




A randomized double-blind placebo-controlled phase II trial of first-line combination chemotherapy with Nintadenib for patients with advanced or recurrent endometrial cancer

ENGOT-EN1-NSGO / FANDANGO



Stratifications

- stage of disease (stage 3 vs. stage 4 vs. recurrent disease)
- Prior adjuvant chemotherapy (yes/no)
- Disease status (no macroscopic disease vs. macroscopic disease)

Trial Status

- Protocol draft to collaborative groups/BI
 - Feasibility of all groups (synopsis, budget, site)
 - NSGO-BI & NSGO-CRO contract
 - NSGO-collect
 - **BI-NSGO grant contract is under development**
 - **BI has accepted the grant amount**
 - **BI-NSGO agreed to sign contract (deadline June 18 2015)**
- May 14
- June-July 14
- Sept-Oct 14
- Oct 14

ENGOT-EN1-NSGO / FANDANGO